Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

16.64 -0.32 (-1.92%)
Streaming Delayed Price Updated: 1:39 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Is ADMA Biologics Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Is ADMA Biologics Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ADMA Biologics Inc (NASDAQ:ADMA) Emerges as a Top GARP Investment Candidate ↗
ADMA Biologics exemplifies GARP investing with strong revenue & earnings growth, high profitability, and a reasonable valuation relative to its biotech peers. 
Via Chartmill
News headline image
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
This Small-Cap Fund Just Dumped $7 Million in ADMA Stock — Here’s Why ↗
This Small-Cap Fund Just Dumped $7 Million in ADMA Stock — Here’s Why 
Via The Motley Fool
News headline image
How Is The Market Feeling About ADMA Biologics? ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
ADMA Biologics Earnings Preview ↗
 
Via Benzinga
News headline image
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025
Conference Call Scheduled for November 5, 2025, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Groupon Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Adma Biologics (ADMA) Q2 Revenue Up 14% ↗
Via The Motley Fool
Topics Economy
News headline image
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA BIOLOGICS INC (NASDAQ:ADMA) - A Strong Growth Candidate Meeting Minervini's Criteria ↗
ADMA Biologics (NASDAQ:ADMA) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors. 
Via Chartmill
News headline image
ADMA BIOLOGICS INC (NASDAQ:ADMA) – A Strong Growth Stock with Technical Breakout Potential ↗
ADMA Biologics (NASDAQ:ADMA) shows strong growth fundamentals and a technical breakout setup, making it a stock to watch in the biotech sector. 
Via Chartmill
News headline image
ADMA BIOLOGICS INC (NASDAQ:ADMA) – A High Growth Momentum Stock with Strong Technical Setup ↗
ADMA Biologics (NASDAQ:ADMA) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has outperformed peers and may present a breakout... 
Via Chartmill
News headline image
ADMA BIOLOGICS INC (NASDAQ:ADMA) – A Promising Affordable Growth Stock ↗
ADMA Biologics (NASDAQ:ADMA) shows strong growth, reasonable valuation, and solid financial health, making it an attractive candidate for investors seeking affordable growth stocks in the biotech... 
Via Chartmill
News headline image
ADMA BIOLOGICS INC (NASDAQ:ADMA) is not too expensive for the growth it is showing. ↗
Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
News headline image
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits ↗
The company makes immunoglobulin products using donated plasma. 
Via Investor's Business Daily
Topics Earnings
News headline image
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
3 Mid-Cap Medical Stocks Outperforming the Market
Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness. 
Via MarketBeat
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.